$78.20−0.48 (−0.61%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Tarsus Pharmaceuticals (TARS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~67.7%/yr (FY21→FY25), net margin −14.7%. Worth your attention in FY25: Share count (+103.3%) and Capex step-up ($9.9M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲146.7%
451.4
FY21→FY25CAGR +67.7%/yr
Net income ($M)▲42.5%
−66.4
FY21→FY25CAGR —
Free cash flow ($M)▲73.6%
−22.3
capex stepped upCAGR —
Diluted EPS▲48.2%
−1.59
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+103.3%
20.6mn → 41.8mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$9.9M
▲529% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-15¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 96.4% → 93.2%. Net margin -14.7% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 682,203.0 | 451,360.0 | 182,953.0 | 17,447.0 | 25,816.0 | 57,027.0 | ▲146.7% | +67.7% |
Cost of revenue | 46,330.0 | 30,684.0 | 12,826.0 | 1,593.0 | 955.0 | 2,075.0 | ▲139.2% | +96.1% |
Gross profit | 635,873.0 | 420,676.0 | 170,127.0 | 15,854.0 | 24,861.0 | 54,952.0 | ▲147.3% | +66.3% |
Research & development | 747,764.0 | 64,322.0 | 53,386.0 | 50,312.0 | 42,624.0 | 41,712.0 | ▲20.5% | +11.4% |
Selling, general & admin | 585,829.0 | 427,323.0 | 237,310.0 | 108,700.0 | 44,949.0 | 25,397.0 | ▲80.1% | +102.5% |
Total operating expenses | 1,331,973.0 | 491,645.0 | 290,696.0 | 159,012.0 | 87,573.0 | 67,109.0 | ▲69.1% | +64.5% |
Operating incomefeeds ROC rank | −696,100.0 | −70,969.0 | −120,569.0 | −143,158.0 | −62,712.0 | −12,157.0 | ▲41.1% | — |
Other income, net | 5,644.0 | 6,610.0 | 5,015.0 | 7,265.0 | 617.0 | −1,615.0 | — | — |
Pretax income | −690,456.0 | −64,359.0 | −115,554.0 | −135,893.0 | −62,095.0 | −13,772.0 | ▲44.3% | — |
Income tax | 11,769.0 | 2,059.0 | 0.0 | 0.0 | −4.0 | 55.0 | — | +147.4% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −702,225.0 | −66,418.0 | −115,554.0 | −135,893.0 | −62,091.0 | −13,827.0 | ▲42.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −15.16 | −1.59 | −3.07 | −4.62 | −2.52 | −0.67 | ▲48.2% | — |
Diluted shares (mn) | 46.42 | 41.78 | 37.60 | 29.38 | 24.62 | 20.55 | ▲11.1% | +19.4% |
| Margins | ||||||||
Gross margin89th pct in Healthcare | 93.2% | 93.2% | 93.0% | 90.9% | 96.3% | 96.4% | ▲0.2pp | −3.2pp |
Operating margin | −102.0% | −15.7% | −65.9% | −820.5% | −242.9% | −21.3% | ▲50.2pp | +5.6pp |
Net margin10th pct in Healthcare | −102.9% | −14.7% | −63.2% | −778.9% | −240.5% | −24.2% | ▲48.4pp | +9.5pp |
† TTM = trailing four quarters through 2026-09-30.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-23 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Tarsus Pharmaceuticals' revenue last fiscal year?
Tarsus Pharmaceuticals reported revenue of $451.4M in fiscal 2025, up 146.7% from fiscal 2024.
What was Tarsus Pharmaceuticals' net income?
Tarsus Pharmaceuticals reported net income of −$66.4M in fiscal 2025, a net margin of −14.7%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

